1. Home
  2. RCEL vs SLN Comparison

RCEL vs SLN Comparison

Compare RCEL & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCEL
  • SLN
  • Stock Information
  • Founded
  • RCEL 2020
  • SLN 1994
  • Country
  • RCEL United States
  • SLN United Kingdom
  • Employees
  • RCEL N/A
  • SLN N/A
  • Industry
  • RCEL Medical/Dental Instruments
  • SLN Biotechnology: Pharmaceutical Preparations
  • Sector
  • RCEL Health Care
  • SLN Health Care
  • Exchange
  • RCEL Nasdaq
  • SLN Nasdaq
  • Market Cap
  • RCEL 342.7M
  • SLN 352.2M
  • IPO Year
  • RCEL N/A
  • SLN N/A
  • Fundamental
  • Price
  • RCEL $11.77
  • SLN $6.88
  • Analyst Decision
  • RCEL Hold
  • SLN Strong Buy
  • Analyst Count
  • RCEL 3
  • SLN 4
  • Target Price
  • RCEL $16.50
  • SLN $61.50
  • AVG Volume (30 Days)
  • RCEL 96.7K
  • SLN 691.1K
  • Earning Date
  • RCEL 02-20-2025
  • SLN 11-14-2024
  • Dividend Yield
  • RCEL N/A
  • SLN N/A
  • EPS Growth
  • RCEL N/A
  • SLN N/A
  • EPS
  • RCEL N/A
  • SLN N/A
  • Revenue
  • RCEL $60,040,000.00
  • SLN $21,773,221.00
  • Revenue This Year
  • RCEL $40.34
  • SLN N/A
  • Revenue Next Year
  • RCEL $52.79
  • SLN $104.98
  • P/E Ratio
  • RCEL N/A
  • SLN N/A
  • Revenue Growth
  • RCEL 32.24
  • SLN N/A
  • 52 Week Low
  • RCEL $7.51
  • SLN $5.81
  • 52 Week High
  • RCEL $18.93
  • SLN $27.72
  • Technical
  • Relative Strength Index (RSI)
  • RCEL 43.48
  • SLN 32.78
  • Support Level
  • RCEL $11.30
  • SLN $5.96
  • Resistance Level
  • RCEL $12.75
  • SLN $8.88
  • Average True Range (ATR)
  • RCEL 0.74
  • SLN 0.73
  • MACD
  • RCEL -0.24
  • SLN 0.27
  • Stochastic Oscillator
  • RCEL 18.01
  • SLN 33.77

About RCEL Avita Medical Inc.

Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult patients in the US with paediatric clinical trials and expanded indications in soft-tissue reconstruction and vitiligo underway. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

Share on Social Networks: